相关实验视频

Updated: May 8, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

对由GLP-1RAs引起的胃肠道不良反应进行风险因素查和预测建模

Rui Gao¹, Yue Li^1,2, Anan Li³

¹Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.

Frontiers in endocrinology

|December 24, 2024

概括

这项研究确定了年龄,性别,先前的胃肠道问题和药物作为2型糖尿病 (T2DM) 患者的胃肠道副作用 (GISE) 的关键风险因素,这些患者接受了与葡萄糖类-1受体激活剂 (GLP-1RAs) 治疗. 开发了一个预测模型来评估这些患者的GISE风险.

科学领域:

内分泌学和新陈代谢学
药理学药理学是指药理学的学科.
现实世界的证据研究研究.

背景情况:

2型糖尿病 (T2DM) 的管理通常涉及葡萄糖类-1受体激活剂 (GLP-1RAs).
胃肠道副作用 (GISEs) 是与GLP-1RA治疗相关的常见不良事件.
预测GISE对于优化T2DM治疗和患者坚持治疗至关重要.

研究的目的:

为了确定使用GLP-1RAs的T2DM患者GISE的风险因素.
开发和验证使用现实数据对与GLP-1RA相关的GISE进行预测模型.

主要方法:

对855名用GLP-1RAs治疗的T2DM患者的回顾性分析.
多因素后勤回归以确定风险因素 (年龄,性别,胃肠道病史,药物计数).
使用培训和验证集构建和验证一个名ogram预测模型.

主要成果:

年龄,性别,胃肠道疾病史和口服药物组合的数量是GISE的显著风险因素 (p < 0.05).
诺莫格拉姆模型表现出良好的区分能力 (AUC:0.855培训,0.836验证) 和准确性.
决策曲线分析证实了该模型在预测GISE方面的临床实用性.

结论:

一种名谱模型有效地预测T2DM患者GLP-1RA诱导的GISE.
该模型包含了风险分层的关键临床因素.
这种工具可以帮助临床医生管理GLP-1RA治疗并减轻副作用.

关键词:

胃肠道的副作用葡萄糖类-1受体激动剂的葡萄糖类-1受体激动剂.这个名字是名ogramogram.有关风险因素的风险因素.2型糖尿病是什么?

更多相关视频

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Assessment of the Gastrointestinal System I: Subjective Data

Assessment of the Gastrointestinal System I: Subjective Data

Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...